Listeria Monocytogenes Infections Treatment Global Market Report 2024

The listeria monocytogenes infections treatment market size has grown strongly in recent years. It will grow from $4.52 billion in 2023 to $4.79 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. Historical growth in addressing Listeria monocytogenes infections was largely driven by factors such as the implementation of stricter food safety regulations, a rise in the frequency of foodborne illnesses, advancements in diagnostic methods, educational awareness programs, and improvements in healthcare infrastructure.

The listeria monocytogenes infections treatment market size is expected to see strongly grown in the next few years. It will grow to $5.86 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. Anticipated growth in managing Listeria monocytogenes infections in the forecast period is linked to several factors, including the globalization of food supply chains, ongoing research and development efforts in antimicrobial treatments, shifts in dietary patterns, increased international collaboration in healthcare, and a heightened focus on public health preparedness.

The listeria monocytogenes infection treatment market is poised for growth owing to the increasing prevalence of foodborne diseases. These illnesses, stemming from consuming contaminated food or beverages, encompass concerns related to listeria monocytogenes infections. The treatment for such infections mitigates risks and curbs the severity of the disease. Notably, in December 2022, the European Food Safety Authority reported a 29.8% surge in foodborne incidents, recording approximately 4,005 cases in 2021 compared to the previous year. This escalation underscores the pivotal role of the rising foodborne disease incidence in propelling the listeria monocytogenes infection treatment market.

Government-led initiatives in healthcare research and development are set to bolster the listeria monocytogenes infection treatment market. These initiatives encompass targeted actions, policies, or funding programs by government entities to address healthcare concerns. Notably, the UK government's commitment of £260 million (US $270.65 million) in 2022 towards healthcare research and manufacturing stands as a testament to this drive. This substantial funding aims to support NHS-led health research, privacy-preserving platforms for diagnostics and treatment, and the expansion of life sciences manufacturing. Such governmental backing significantly impacts the growth trajectory of the listeria monocytogenes infection treatment market. The listeria monocytogenes infection treatment market is set to expand further owing to the escalating healthcare expenditure. This expenditure represents the cumulative spending on healthcare-related goods and services within an economy or healthcare system. The increased allocation of funds plays a pivotal role in fostering the development and accessibility of listeria monocytogenes infection treatment. For instance, in November 2022, healthcare expenditure in Canada surged to $331 billion, marking an increase of 0.8% from the previous year's 7.6%. This upward trend in healthcare expenditure significantly fuels the growth dynamics of the listeria monocytogenes infection treatment market.

Key companies in the listeria monocytogenes infection treatment market are prioritizing innovation, exemplified by products like Microgen Listeria-ID. This microbiological test, launched by Gold Standard Diagnostics in April 2023, enables the detection and confirmation of Listeria bacteria in food and environmental samples. Microgen Listeria-ID offers a comprehensive identification process, swiftly detecting and distinguishing Listeria spp species without additional materials. Renowned for its rapid and reliable identification, this test significantly expedites quality control measures and monitoring in food processing facilities, contributing to market revenue and efficiency.

In September 2022, Team Arnav Foundation, a US-based nonprofit group focused on finding treatment for juvenile sarcoma cancer, partnered with OS Therapies LLC. With this partnership, Team Arnav Foundation supports the phase IIb trial of OST-HER2 (Listeria monocytogenes) in recurrent, resected osteosarcoma. Additionally, Team Arnav's primary mission is to fund research that would lead to better treatments, higher cure rates, and reduced side effects for patients with malignant bone and soft tissue cancers. OS Therapies LLC is a US-based clinical-stage therapeutic company that develops immunotherapies based on live attenuated listeria monocytogenes (Lm) for solid tumors such as osteosarcoma.

Major companies operating in the listeria monocytogenes infections treatment market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Biogen Inc., Vertex Pharmaceuticals Incorporated, Fresenius Kabi AG, Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., ZydusCadila Health Care Ltd., Emergent Bio Solutions Inc., Wockhardt Ltd., Hainan Poly Pharm Co. Ltd., Novel Laboratories Inc., Bionpharma Inc., LimmaTech Biologics AG.

North America was the largest region in the listeria monocytogenes infections treatment market in 2023. The regions covered in the listeria monocytogenes infections treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the listeria monocytogenes infections treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main classes of drugs used for listeria monocytogenes infections treatment are Ampicillin, Gentamicin, Vancomycin, and others. Several types of infections include gastroenteritis, endocarditis, meningitis, bacteremia, and brain abscess. The drugs can be administered through various modes, such as oral, injectable, and other modes and are used by several end users, including hospitals, home care, specialty clinics, and others.

The listeria monocytogenes infections treatment market research report is one of a series of new reports provides listeria monocytogenes infections treatment market statistics, including listeria monocytogenes infections treatment industry global market size, regional shares, competitors with a listeria monocytogenes infections treatment market share, detailed listeria monocytogenes infections treatment market segments, market trends and opportunities, and any further data you may need to thrive in the listeria monocytogenes infections treatment industry. This listeria monocytogenes infections treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The listeria monocytogenes infections treatment market consists of revenues earned by entities by provide services such as diagnosis, antibiotic therapy, medical consultations, and nutritional support. The market value includes the value of related goods sold by the service provider or included within the service offering. The listeria monocytogenes infections treatment market also includes sales of penicillin G, meropenem, and trimethoprim-sulfamethoxazole (TMP-SMX). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.